Your support fuels our research to #EndALS! Donate Now
10/25/2021
ALS TDI: The Drug Discovery Engine for ALS

Recently, ALS TDI took an opportunity to reintroduce ourselves. If you follow us on social media, read our emails, or check our website you may have noticed that we have a new way of describing our role in the effort to end ALS – that we are the Drug Discovery Engine for ALS.

What do we mean by drug discovery engine? It means that our mission is to discover and invent new ALS treatments, and work to advance those treatments into human trials – and to do it over and over again until there are treatments for everyone living with ALS.

Recently, our CEO and Chief Scientific Officer Fernando Vieira gave a presentation at one of our ALS TDI Town Halls to explain more about what we’re doing to fulfill this mission, and what it means to be the Drug Discovery Engine for ALS.

Today, on endpoints, we’re featuring that presentation for anyone who wasn’t able to attend or wants to learn more about ALS TDI and our research to end ALS.

Recently, ALS TDI took an opportunity to reintroduce ourselves. If you follow us on social media, read our emails, or check our website you may have noticed that we have a new way of describing our role in the effort to end ALS – that we are the Drug Discovery Engine for ALS.

What do we mean by drug discovery engine? It means that our mission is to discover and invent new ALS treatments, and work to advance those treatments into human trials – and to do it over and over again until there are treatments for everyone living with ALS.

Recently, our CEO and Chief Scientific Officer Fernando Vieira gave a presentation at one of our ALS TDI Town Halls to explain more about what we’re doing to fulfill this mission, and what it means to be the Drug Discovery Engine for ALS.

Today, on endpoints, we’re featuring that presentation for anyone who wasn’t able to attend or wants to learn more about ALS TDI and our research to end ALS.

Thank you to our Sponsors
Cytokinetics
Biogen
MT Pharma America
Apellis
Insource Services, Inc
Novartis